Meeting
2011 ASCO Annual Meeting
17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma.
Authors
J. F. Moley
Siteman Cancer Center, Washington University, St. Louis, MO
J. F. Moley , D. Adkins , K. C. Bible , A. M. Traynor , J. R. Molina , G. Colon-Otero , T. J. Pluard , M. H. Shah , R. Suresh , C. Erlichman , S. P. Ivy , V. Suman , S. M. Geyer , P. M. Fracasso , M. S. Cohen , H. Tang , E. Fialkowski , A. Traugott , R. C. Smallridge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00118248
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5582)
Abstract #
5582
Poster Bd #
17E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
First Author: Jaume Capdevila
Poster
2017 ASCO Annual Meeting
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
First Author: Jiaying Chen
Poster
2024 ASCO Annual Meeting
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.
First Author: Elena Garralda
Poster
2023 ASCO Annual Meeting
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
First Author: Caicun Zhou